30431-99-3

Basic information

• Product Name: ethyl 4-cyanotetrahydro-2H-pyran-4-carboxylate
• Synonyms: ethyl 4-cyanotetrahydro-2H-pyran-4-carboxylate;2H-pyran-4-carboxylic acid, 4-cyanotetrahydro-, ethyl este;ethyl 2-(4-cyanotetrahydro-2H-pyran-4-yl)acetate;Ethyl 4-cyanotetrahydro-2...;ethyl 4-cyanooxane-4-carboxylate;4-cyano-4-tetrahydropyrancarboxylic acid ethyl ester;4-cyanotetrahydropyran-4-carboxylic acid ethyl ester;ethyl 4-cyanotetrahydropyran-4-carboxylate
• CAS NO: 30431-99-3
• Molecular Formula: C₉H₁₃NO₃
• Molecular Weight: 183
• Mol File: 30431-99-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 297.541°C at 760 mmHg
• Flash Point: 128.64°C
• Appearance: /
• Density: 1.125g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ethyl 4-cyanotetrahydro-2H-pyran-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-cyanotetrahydro-2H-pyran-4-carboxylate(30431-99-3)
• EPA Substance Registry System: ethyl 4-cyanotetrahydro-2H-pyran-4-carboxylate(30431-99-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 30431-99-3(Hazardous Substances Data)

Usage

Uses

Ethyl 4-Cyanotetrahydro-2h-pyran-4-carboxylate is used in preparation of Imidazo[1,2-a]pyridinyl derivatives as IRAK4 inhibitors.

InChI:InChI=1/C9H13NO3/c1-2-13-8(11)9(7-10)3-5-12-6-4-9/h2-6H2,1H3

Upstream product

• 111-44-4 3-oxa-1,5-dichloropentane 
• 105-56-6 ethyl 2-cyanoacetate 
• 30431-98-2 4-Vinyloxy-2-cyan-ethylbutanoat 

Downstream Products

• 1010836-56-2 4-(hydroxymethyl)-tetrahydro-2H-pyran-4-carbonitrile 
• 959238-22-3 [4-(aminomethyl)tetrahydro-2H-pyran-4-yl]methanol 
• 5337-04-2 tetrahydro-4H-pyran-4,4-dicarboxylic acid 
• 856067-31-7 4-cyano-tetrahydro-pyran-4-carboxylic acid amide 
• 848821-06-7 4-cyanotetrahydro-2H-pyran-4-carboxylic acid 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.